S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Stock market today: Asian shares mixed after interest rates-driven sell-off on Wall Street
Analysts Recommend These Mining Stocks Before Metal Prices Rally
His system isolated NVIDIA - Here's His Next Buy. (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Stock market today: Asian shares mixed after interest rates-driven sell-off on Wall Street
Analysts Recommend These Mining Stocks Before Metal Prices Rally
His system isolated NVIDIA - Here's His Next Buy. (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Stock market today: Asian shares mixed after interest rates-driven sell-off on Wall Street
Analysts Recommend These Mining Stocks Before Metal Prices Rally
His system isolated NVIDIA - Here's His Next Buy. (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Stock market today: Asian shares mixed after interest rates-driven sell-off on Wall Street
Analysts Recommend These Mining Stocks Before Metal Prices Rally
His system isolated NVIDIA - Here's His Next Buy. (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
NASDAQ:VCEL

Vericel (VCEL) Stock Forecast, Price & News

$34.19
+1.67 (+5.14%)
(As of 09/21/2023 ET)
Compare
Today's Range
$33.03
$34.50
50-Day Range
$31.69
$39.25
52-Week Range
$17.30
$39.90
Volume
468,222 shs
Average Volume
356,377 shs
Market Capitalization
$1.63 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.63

Vericel MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
21.7% Upside
$41.63 Price Target
Short Interest
Bearish
11.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.78mentions of Vericel in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$146,840 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.26) to $0.03 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

899th out of 965 stocks

Biological Products, Except Diagnostic Industry

149th out of 159 stocks


VCEL stock logo

About Vericel (NASDAQ:VCEL) Stock

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

VCEL Price History

VCEL Stock News Headlines

Vericel (NASDAQ:VCEL) Shares Gap Up After Analyst Upgrade
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Vericel (VCEL) Gets a Buy from BTIG
Vericel: A Knee-Jerk 'Hold' Worth Its Salt
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
BTIG Sticks to Its Buy Rating for Vericel (VCEL)
BTIG Upgrades Vericel (VCEL)
Expert Ratings for Vericel
H.C. Wainwright Reaffirms Their Buy Rating on Vericel (VCEL)
Here's what Wall Street expects from Vericel's earnings report
Truist Financial Sticks to Its Hold Rating for Vericel (VCEL)
BTIG Issues a Hold Rating on Vericel (VCEL)
See More Headlines
Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

VCEL Company Calendar

Last Earnings
8/02/2023
Today
9/22/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCEL
Employees
305
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$41.63
High Stock Price Forecast
$44.50
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+21.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-16,710,000.00
Pretax Margin
-6.99%

Debt

Sales & Book Value

Annual Sales
$163.70 million
Book Value
$4.07 per share

Miscellaneous

Free Float
45,165,000
Market Cap
$1.63 billion
Optionable
Optionable
Beta
1.76

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Dominick C. Colangelo Esq. (Age 59)
    CEO, Pres & Director
    Comp: $1.42M
  • Mr. Joseph Anthony Mara Jr. (Age 47)
    CFO & Treasurer
    Comp: $673.44k
  • Mr. Michael HalpinMr. Michael Halpin (Age 62)
    Chief Operating Officer
    Comp: $718.24k
  • Mr. Sean C. FlynnMr. Sean C. Flynn (Age 49)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $593.24k
  • Dr. Jonathan M. Hopper FRCSEd. (Age 61)
    M.B. Ch.B., Chief Medical Officer
    Comp: $615.24k
  • Mr. Jonathan Siegal
    Principal Accounting Officer, VP & Corp. Controller
  • Mr. Eric Burns
    VP of Fin. & Investor Relations
  • Mr. Patrick J. Fowler
    Sr. VP of Corp. Devel. & Strategy
  • Mr. Patrick Helfrich
    VP of Marketing & Commercial Strategy
  • Ms. Heidi Hassen
    Sr. VP of HR













VCEL Stock - Frequently Asked Questions

Should I buy or sell Vericel stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VCEL shares.
View VCEL analyst ratings
or view top-rated stocks.

What is Vericel's stock price forecast for 2023?

4 equities research analysts have issued 1-year target prices for Vericel's shares. Their VCEL share price forecasts range from $39.00 to $44.50. On average, they expect the company's share price to reach $41.63 in the next twelve months. This suggests a possible upside of 21.7% from the stock's current price.
View analysts price targets for VCEL
or view top-rated stocks among Wall Street analysts.

How have VCEL shares performed in 2023?

Vericel's stock was trading at $26.34 at the start of the year. Since then, VCEL stock has increased by 29.8% and is now trading at $34.19.
View the best growth stocks for 2023 here
.

When is Vericel's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our VCEL earnings forecast
.

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) posted its earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. The biotechnology company had revenue of $45.92 million for the quarter, compared to analyst estimates of $42.14 million. Vericel had a negative net margin of 7.39% and a negative trailing twelve-month return on equity of 6.90%. The company's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.19) EPS.

What guidance has Vericel issued on next quarter's earnings?

Vericel issued an update on its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $190.00 million-$197.00 million, compared to the consensus revenue estimate of $190.29 million.

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Who are Vericel's major shareholders?

Vericel's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.02%), Brown Capital Management LLC (14.53%), State Street Corp (5.22%), Conestoga Capital Advisors LLC (4.91%), Fisher Asset Management LLC (3.55%) and New York State Common Retirement Fund (2.23%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends
.

How do I buy shares of Vericel?

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $34.19.

How much money does Vericel make?

Vericel (NASDAQ:VCEL) has a market capitalization of $1.63 billion and generates $163.70 million in revenue each year. The biotechnology company earns $-16,710,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

How many employees does Vericel have?

The company employs 305 workers across the globe.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.vcel.com. The biotechnology company can be reached via phone at (617) 588-5555, via email at ir@vcel.com, or via fax at 617-588-5554.

This page (NASDAQ:VCEL) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -